首页 期刊 中国药理学与毒理学 Isochlorogenic acid A attenuates progression of liver fibrosis through regulating HMGB1/TLR4/NF-κB signaling pathways 【正文】

Isochlorogenic acid A attenuates progression of liver fibrosis through regulating HMGB1/TLR4/NF-κB signaling pathways

作者:LIU; Xin; KUANG; Kai; MEI; Dan; ZHANG; Bo Department; of; Pharmacy; Peking; Union; Medical; College; Hospital; Chinese; Academy; of; Medical; Sciences; and; Peking; Union; Medical; College; Beijing; 100730; China; Key; Laboratory; of; Molecular; Pharmacology; and; Drug; Evaluation(Yantai; University); Ministry; of; Education; Yantai; University; Yantai; 264005; China; Drug; Clinical; Trial; Institution; Wuxi; People; Hospital; Nanjing; Medical; University; Wuxi; 214023; China
isochlorogenic   acid   a   liver   fibrosis  

摘要:OBJECTIVE Liver fibrosis is a chronic damage process related to the further progression of hepatic cirrhosis and has yet no truly effective treatment is available.This study aimed to investigate the effects of isochlorogenic acid A(ICQA)on liver fibrosis induced by carbon tetrachloride(CCl4)and clarify the underlying mechanism.METHODS Rats were treated with CCl4 for eight weeks in order to induce liver fibrosis and simultaneously orally administered with ICQA(10,20 and 40 mg·kg-1).RESULTS ICQA had significant protective effect on liver injury,inflammation,and fibrosis in rats.Meanwhile,ICQA prevented the activation of hepatic stellate cells(HSC)as indicated by inhibiting the overexpres⁃sion of a-smooth muscle actin(a-SMA).In addition,reduced fibrosis was found to be associated with decreased protein expression of high-mobility group box 1(HMGB1)and toll like receptor(TLR)4.Moreover,ICQA supressed the cytoplasmic translocation of HMGB1 in rat liver.Further investigations indicated that ICQA treatment significantly attenuated nuclear translocation of the nuclear factor-κB(NF-κB)p65 and inhibited degradation of IkBa expression in the liver of rats with liver fibrosis.CONCLUSION ICQA has hepatoprotective and anti-fibrotic effects in rats with liver fibrosis through modulating the HMGB1/TLR4/NF-κB signaling pathways.

注:因版权方要求,不能公开全文,如需全文,请咨询杂志社

学术咨询 免费咨询 杂志订阅